{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007795","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.456717+00:00","generated_at":"2026-05-16T14:09:30.996805+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML","bullets":["90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.","78% of responders achieved MRD negativity by central flow cytometry.","No dose-limiting toxicities or drug-related deaths; febrile neutropenia in 2 subjects (16.7%).","Responses seen in FLT3-WT, TP53/complex karyotype, RAS, and MDS-related mutations.","Preliminary data at 160 mg cohort show early blast clearance and MRD negativity."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007795","json":"https://secwatch.observer/filing/0001171843-25-007795.json","markdown":"https://secwatch.observer/filing/0001171843-25-007795.md","text":"https://secwatch.observer/filing/0001171843-25-007795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007795/0001171843-25-007795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007795/f8k_120525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:09:30.996805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}